The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alpha V beta 3 Integrin via Steric Hindrance.
Borst, A.J., James, Z.M., Zagotta, W.N., Ginsberg, M., Rey, F.A., DiMaio, F., Backovic, M., Veesler, D.(2017) Structure 25: 1732-1739.e5
- PubMed: 29033288 
- DOI: 10.1016/j.str.2017.09.007
- Primary Citation of Related Structures:  
5OPY, 6AVQ, 6AVR, 6AVU - PubMed Abstract: 
The LM609 antibody specifically recognizes α V β 3 integrin and inhibits angiogenesis, bone resorption, and viral infections in an arginine-glycine-aspartate-independent manner. LM609 entered phase II clinical trials for the treatment of several cancers and was also used for α V β 3 -targeted radioimmunotherapy ...